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The actuarial late complication rate grade 3 was 1.1% for the bladder and 3.4% for the bowel and rectum. One patient suffered a
GI grade 4 complication. Vagina shortening and obliteration occurred in 18.8%.
Conclusions. This series suggests that 45Gy to the whole pelvis combined with ﬁve fractions of 5.5–6Gy to point A with HDR
brachytherapy in conjunction with concomitant chemotherapy is an effective and safe fractionation schedule in the treatment
of stages IB to IVB of cervix cancer.
http://dx.doi.org/10.1016/j.rpor.2013.03.244
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Purpose. Undifferentiated Uterine Sarcoma (UUS) is a rare, not well known and aggressive disease. We retrospectively analysed
the outcome of 13 patients diagnosed and treated at our centre.
Material and methods. From 1979 to 2010 the records and pathology of 13 patients diagnosed and treated for UUS were retrospec-
tively analysed. Three patients had metastasis at diagnosis; 10 out 13 patients underwent surgery with a curative aim followed by
radiation therapy (RT) in 8 patients (external beam radiotherapy and/or brachytherapy). Chemotherapy (ChT) was administered
as an adjuvant treatment in 3 patients. The Kaplan–Meier actuarial method was used to analyse the overall survival (OS) and a
descriptive analysis was used to know the frequencies.
Results. Median follow-up of the entire series was 16 months (2–276 months, mean 50,08). The mean age of the group was 66 years.
FIGO 2009 stage: 3 IA, 5 IB, 2 IIB and 3 IVB. Patients with stage I developed 2 local relapses (in the only 2 no irradiated patients)
and 3 distant metastasis; 50% of this group were long survivors. All patients in stage II developed distant metastasis. Distant
metastasis was observed in 61.5% of the entire series. A half of patients treated with adjuvant RT were alive at the moment of
the analysis, and no evidence of local relapse was viewed. The 3 patients that received adjuvant ChT died because progression of
the disease (median survival 12 months). The median OS was 16 months (mean 77,8); for stage I was 17 months, being 9 months
in the remaining patients (mean 126 vs14).
Conclusions. Poor outcome of UUS was associated with a high incidence of distant metastasis. Stage was the strongest predictor
of bad outcome. Adjuvant RT seems to beneﬁt these patients with 50% of long survivors. New treatment strategies should be
considered in patients in whom distant metastasis are not found at diagnosis.
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Introduction. Intracavitary brachytherapy, an essential part of any deﬁnitive treatment of locally advanced cervical cancer, is
associated to aches andpain of varying intensity. For the proper insertion of devices as applicators, it is essential to immobilize the
patient, the tumour and the surrounding organs. The presence of anaesthesiologists in Brachytherapy Units is strictly necessary.
Objectives. Evaluate the anaesthetic procedure in gynaecologic intracavitary brachytherapy in cervical cancer as standard practice.
Material and methods. 33 patients with locally advanced cervical cancer underwent to high dose rate Ir192 (HDR) gynaecologic
intracavitary brachytherapy between 2010/2011. Median age was 55.81 (34–82) and 132 fractions. Patients were examined in the
preanaesthesia consultation and signed the informed consent. The majority were classiﬁed based on the American Society of
Anestesiologist (ASA) III (63,64%). Anaesthetic technique chosen was total intravenous anaesthesia (TIVA), induction and main-
tenance with propofol and remifentanil/fentanyl to maintain hemodynamic stability and the adequate degree of immobilization.
Spontaneous ventilation with face masks or laryngeal mask (LM) or mechanical ventilation with LM or orotracheal intubation
was used. 11% required the use of muscular relaxants. Patients were transferred to the simulation room, and then moved to the
isolation room for treatment.
Results. At the end of the procedure, patients were lucid, supportive and without pain. No patient experienced nausea or vomi-
ting nor required additional analgesia in the surgical room. They did not present any acute nor late complications related to
anaesthesia. TIVA is well tolerated and provides good anaesthetic quality.
Conclusions. TIVA based on propofol and remifentanilo has a safety proﬁle, fast metabolism and elimination. It is adequate
technique for short procedure such as intracavitary gynaecologic brachytherapy on an outpatient basis and no complications
were observed. Standard criteria for medical discharge are met at an earlier stage, signiﬁcantly shortening the patient’s stay at
the hospital and minimize costs.
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